{"id":8297,"date":"2025-12-03T09:40:55","date_gmt":"2025-12-03T09:40:55","guid":{"rendered":"http:\/\/echonews.fr\/?page_id=8297"},"modified":"2025-12-03T14:06:05","modified_gmt":"2025-12-03T14:06:05","slug":"ovarian-cancer","status":"publish","type":"page","link":"http:\/\/echonews.fr\/?page_id=8297","title":{"rendered":"Ovarian cancer"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Bibliographic and Educational Resources in Gynecologic Oncology<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

This platform is designed to serve as a comprehensive educational and bibliographic resource for healthcare professionals involved in Gynecologic Oncology.<\/span><\/strong> Covering a wide range of up-to-date topics within the field, it offers structured access to recent scientific literature and a variety of pedagogical tools tailored to clinicians, educators, and trainees.<\/p>

Each topic is grounded in a curated selection of recent publications, accompanied by in-depth summaries that go far beyond traditional abstracts<\/strong><\/span>\u2014offering clear, clinically relevant insights without the time burden of reading full articles. These summaries act as gateways to the original literature, helping users identify which articles warrant deeper exploration.<\/p>

In addition to these detailed reviews, users will find a rich library of supplementary materials<\/span><\/strong>: topic overviews, FAQs, glossaries, synthesis sheets, thematic podcasts, fully structured course outlines adaptable for teaching, and ready-to-use PowerPoint slide decks. All resources are open access and formatted for easy integration into academic or clinical training programs.<\/p>

By providing practical, well-structured content, the platform enables members of the cytogenomics community to efficiently update their knowledge on selected topics. It also offers educational materials that are easily adaptable for instructional use.<\/span><\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Early Detection of Ovarian Cancer: Limits of Current Strategies and Emerging Innovations<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Dr C\u00e9cile Dupont<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\tHm-envelop<\/span>\n\t\t\t\t\t\t<\/i>\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\tLinkedin<\/span>\n\t\t\t\t\t\t<\/i>\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Dr Pierre durand<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\tHm-envelop<\/span>\n\t\t\t\t\t\t<\/i>\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\tYoutube<\/span>\n\t\t\t\t\t\t<\/i>\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\tLinkedin<\/span>\n\t\t\t\t\t\t<\/i>\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tOVERVIEW<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t1. Introduction<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Ovarian cancer remains one of the most lethal malignancies affecting women, largely due to its asymptomatic onset, rapid dissemination, and the lack of effective early detection strategies. High-grade serous ovarian cancer (HGSOC), the most common subtype, accounts for the majority of advanced-stage diagnoses and ovarian cancer\u2013related deaths. Despite decades of research and several large-scale randomized controlled trials, population-based screening has failed to demonstrate any reduction in mortality. Understanding why these programs have not succeeded requires an integrated view of tumor biology, diagnostic limitations, and the potential offered by emerging technologies.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t2. Biological Barriers to Early Detection<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Recent studies, including growth kinetics analyses, have shed light on the intrinsic aggressiveness of HGSOC. Tumors arising from serous tubal intraepithelial carcinoma (STIC) lesions grow extremely rapidly and disseminate early. Serial radiological assessments demonstrate short volume doubling times\u2014approximately 2.2 months for ovarian\/pelvic lesions and 1.8 months for omental lesions<\/strong>\u2014reflecting an explosive growth pattern. Simulations indicate that up to 27% of tumors metastasize before being detectable<\/strong> by standard ultrasound or CA125-based screening, and even for the remaining cases, the detection window before metastatic spread is often less than five months<\/strong>. These findings explain why conventional annual or even semiannual screening approaches cannot intercept disease early enough to affect survival.<\/p>

Moreover, symptoms of early HGSOC are minimal or nonspecific. Tumor cells disseminate across the peritoneal cavity long before sizable masses develop in the ovary or pelvis. By the time disease becomes detectable, micrometastatic implants may already be established throughout the abdomen, rendering the cancer effectively \u201cadvanced\u201d from a biological standpoint even if imaging suggests an early stage.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t3. Limitations of Current Screening Modalities<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Traditional screening approaches rely primarily on transvaginal ultrasound (TVUS)<\/strong> and serum CA125<\/strong> measurements. However, both tools have proven insufficient. CA125 is an imperfect biomarker: it lacks specificity, can be elevated in benign conditions, and is not consistently expressed by all ovarian tumors. Serial CA125 interpreted using dynamic algorithms such as ROCA improves sensitivity but still fails to reduce mortality, as demonstrated in the UKCTOCS trial.<\/p>

Ultrasound imaging, while excellent for characterizing masses when performed by expert operators, has limited sensitivity for detecting small, early-stage disease. Early HGSOC does not always present as a discrete mass, and subtle signs can be missed\u2014especially by less experienced examiners. Trials such as PLCO showed that routine TVUS leads to excessive false positives, unnecessary surgeries, and psychological harm without survival benefit.<\/p>

Professional organizations, including ESGO, ESMO, and USPSTF, now strongly recommend against population-based ovarian cancer screening in asymptomatic, average-risk women. The high false-positive rate and the very small margin between detectability and metastatic spread make current strategies impractical on a population scale.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t4. Diagnostic Imaging: Current Challenges and New Horizons<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Ultrasound remains central to the diagnostic pathway once a mass is identified, but its effectiveness varies according to examiner expertise. Recent work assessing interobserver reliability using standardized videoclips shows that even trained examiners may face challenges in evaluating infiltration outside the pelvis. Performance declines significantly in the upper abdomen, reflecting anatomical complexity and operator dependence. These limitations underscore the need for technological assistance.<\/p>

Artificial intelligence represents a major breakthrough in this field. A large international multicentric validation study demonstrated that transformer-based AI models outperform both expert and non-expert examiners<\/strong> in classifying ovarian lesions. Trained on thousands of images from multiple centers and ultrasound systems, these models showed strong generalization capabilities and higher diagnostic accuracy across all statistical metrics. Beyond improving consistency, AI-driven triage could reduce referrals to specialists by more than 60%, alleviating workforce shortages and streamlining clinical pathways. Although AI does not yet solve the fundamental problem of detecting microscopic or preclinical disease, it significantly enhances the accuracy of evaluating detectable lesions.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t5. Emerging Biomarkers and Molecular Technologies<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Because imaging and CA125 are insufficient, attention has turned to molecular detection strategies capable of identifying early-stage disease. Among these, liquid biopsy<\/strong>, tumor-derived cell-free DNA<\/strong>, and circulating tumor cells<\/strong> are promising but still require large-scale validation. The heterogeneity of ovarian cancer and its low tumor burden in early stages pose challenges to sensitivity.<\/p>

Nanotechnology offers a transformative approach. A systematic review of nanoparticle-based diagnostic methods shows exceptional sensitivity and specificity, often surpassing 90% for early-stage disease in experimental settings. Nanobiosensors, nano-enhanced imaging agents, and molecular nanocarriers can detect biomarkers at extremely low concentrations, potentially enabling detection before tumors become radiologically visible.<\/p>

A particularly innovative example is the development of aggregation-induced emission (AIE) probes<\/strong>, such as TPAG. This molecular platform exhibits ultrasensitive detection of salivary \u03b1-amylase, with detection limits far below conventional assays. More importantly, TPAG targets \u03b2-galactosidase<\/strong>, an enzyme overexpressed in ovarian cancer cells, enabling rapid tumor imaging and phototherapeutic applications. Such dual-function probes exemplify the future direction of \u201ctheranostics,\u201d where a single nanostructure can detect and treat disease.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t6. Integrating Innovations into Future Screening Paradigms<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

While no single emerging technology is ready to replace current screening practices, a combination of advanced imaging (AI-enhanced), molecular biomarkers (liquid biopsy, AIE-based probes), and nanotechnology-based sensors may ultimately overcome the barriers posed by tumor biology. The goal is to shift from sporadic, low-sensitivity screening to continuous, high-resolution biological monitoring<\/strong>, potentially through noninvasive samples such as saliva, blood, or even uterine lavage.<\/p>

Until such tools are validated, the primary focus remains on improving diagnostic pathways for symptomatic or incidental findings, refining risk stratification among high-risk groups, and accelerating translation of promising technologies into clinical trials.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tFAQ<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t1. Why is early detection of ovarian cancer so difficult?<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

HGSOC grows rapidly, disseminates early, and remains asymptomatic at low volume. Tumor doubling times of 1.8\u20132.2 months and early peritoneal spread mean that metastasis often occurs before screening can detect disease.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t2. Why do CA125-based screening programs fail to reduce mortality?<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

CA125 lacks specificity and sensitivity, varies with benign conditions, and is not elevated in all tumors. Even when dynamic algorithms improve detection, the preclinical window is too short to intercept disease before spread.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t3. Why is transvaginal ultrasound insufficient for population screening?<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Ultrasound detects masses only after they reach a certain size. Early HGSOC often presents diffusely, without a discrete ovarian mass. False positives lead to unnecessary interventions, while many early cancers remain invisible.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t4. How fast does HGSOC grow according to growth kinetics studies?<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Lesions double in volume every 1.8 months (omentum) to 2.2 months (ovaries\/pelvis). The median interval before metastasis may be as short as 13 months.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t5. What is the \u201cwindow of opportunity\u201d for screening?<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Simulation studies suggest that only 4\u20135 months exist, on average, between detectability by ultrasound\/CA125 and the onset of metastasis \u2014 far too short for annual or biennial screening.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t6. Why did the UKCTOCS trial fail to reduce ovarian cancer mortality?<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Despite earlier-stage detection, mortality did not drop because tumors had already spread microscopically before clinical or screening detection.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t7. What are the main harms of population-based screening?<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

High false-positive rates, psychological distress, invasive surgeries, and complications \u2014 without corresponding survival benefit.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t8. Do major medical societies recommend screening for average-risk women?<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

No. ESGO, ESMO, ACOG, and USPSTF do not<\/strong> recommend routine screening for asymptomatic, average-risk women due to lack of efficacy and high harm rates.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t9. Can expert ultrasound improve early detection?<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

It improves diagnosis<\/strong> but not screening<\/strong>. Expert examiners can characterize known lesions accurately, but cannot detect microscopic or flat early disease.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t10. What do studies show about variability among ultrasound examiners?<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Interobserver performance is high in the pelvis but markedly lower in upper abdominal sites. Experience influences confidence but not uniformly accuracy.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t11. How can artificial intelligence improve ovarian cancer detection?<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

AI models using transformer architectures outperform expert examiners in classifying ovarian lesions, improving sensitivity, specificity, and reducing diagnostic variability.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t12. Does AI solve the problem of early, preclinical detection?<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

No. AI improves classification once a lesion is visible but cannot detect microscopic or pre-mass disease. It addresses diagnostic accuracy, not screening biology.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t13. What are the most promising emerging biomarkers?<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Cell-free DNA signatures, tumor-related microRNAs, \u03b2-galactosidase overexpression, and nanotechnology-enhanced biosensors show high experimental sensitivity.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t14. What is the role of nanotechnology in early detection?<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Nanobiosensors and nanoparticles allow ultrasensitive detection of minute biomarker concentrations, potentially before radiological detectability.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t15. What are AIEgens, and how do they support early detection?<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Aggregation-Induced Emission (AIE) probes emit fluorescence when aggregated. AIEgens like TPAG can detect \u03b1-amylase with ultra-low limits and target \u03b2-galactosidase in ovarian cancer cells for rapid imaging.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t16. What makes TPAG significant for ovarian cancer diagnosis?<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

TPAG binds cells overexpressing \u03b2-galactosidase \u2014 a biomarker linked to ovarian cancer \u2014 enabling rapid imaging and even phototherapy in experimental models.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t17. What is radiomics, and how might it help?<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Radiomics extracts quantitative imaging features invisible to the naked eye. Combined with AI, it could detect subtle patterns enabling earlier recognition of malignant transformation.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t18. Are saliva-based tests promising?<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Yes. Salivary biomarkers like \u03b1-amylase measured by nanoprobes show high accuracy and are minimally invasive, allowing repeated monitoring.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t19. Is liquid biopsy viable for early ovarian cancer?<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

It remains promising but is not yet validated for population screening. Early-stage ovarian cancer often sheds few circulating tumor components.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t20. What is the future direction for effective early detection?<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Continuous multimodal monitoring using nanotechnology, AI, radiomics, and liquid biopsy \u2014 rather than infrequent imaging \u2014 likely represents the future of early detection paradigms.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tBIBLIOGRAPHY<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t1<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Narayanan B, Buddenkotte T, Smith H, et al.<\/strong>
Growth kinetics of high-grade serous ovarian cancer: implications for early detection.<\/em>
British Journal of Cancer. 2025;133:533\u2013538.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\tIs screening failing because of limitations of the tests, or because HGSOC biology makes effective early detection inherently impossible?<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t
1\/ Background and Rationale<\/strong><\/h5>

High-grade serous ovarian cancer (HGSOC) is the most lethal gynecologic malignancy. Most patients present with advanced-stage disease, and 5-year survival is dramatically lower than for early-stage cases. Large randomized trials (UKCTOCS and PLCO) have shown that screening with CA125 and transvaginal ultrasound does not<\/strong> reduce ovarian cancer mortality, despite sometimes leading to earlier-stage diagnoses.<\/p>

This paradox prompted a key question:<\/p>

Is screening failing because of limitations of the tests<\/strong>, or because HGSOC biology makes effective early detection inherently impossible<\/strong>?<\/p>

Previous modelling work had attempted to estimate the growth rate and \u201cpreclinical detectable period\u201d (PCDP) of ovarian cancers, but these models often relied on indirect data (such as single time-point tumor volumes or stage distributions) and made assumptions about tumor size at initiation and at clinical detection. Direct empirical data on longitudinal growth of actual HGSOC lesions<\/strong> were scarce.<\/p>

The authors therefore aimed to analyze real-world serial imaging of HGSOC to derive observed growth kinetics<\/strong> and then use these data in mathematical models to understand the realistic window for early detection and why screening has failed.<\/p>

2\/ Objectives<\/strong><\/h5>

The main objectives were:<\/p>

  1. To quantify the growth rates<\/strong> (volume doubling times) of HGSOC lesions at: